2 names are moving together; 100% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | Healthcare | +3.1% | Group member |
| APGE | Apogee Therapeutics, Inc. | Healthcare | +0.2% | Most structurally connected |
Cohort
2 namesParticipation
100% this sessionObserved history
1 daily buildsFiling coverage
2/2 membersproduct pipeline / R&D affecting expense
“The increase of $46.8 million was primarily driven by further development of our zumilokibart (APG777) program, increases in personnel costs and equity-based compensation, associated with the growth in our research and development team, and increases in external-discovery related costs and other expenses, partially offset by decreases in expenses related to our APG990/APG279, APG333/APG273 and APG808 programs.”
APGE 10-K
product pipeline / R&D
“The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development.”
APGE 10-K
supply chain
“Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders’ equity.”
APGE 10-Q
Inflammatory Disease Biologics can stay leader-led if secondary names fail to join while APGE keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.